In the last century, global pandemics have been primarily driven by respiratory infections, which consistently rank among the top 20 causes of death worldwide. The coronavirus disease 2019 (COVID-19) pandemic has underscored the intricate nature of managing multiple health crises simultaneously. In recent years, climate change has emerged as a major biosafety and population health challenge. Global warming and extreme weather events have intensified outbreaks of climate-sensitive infectious diseases, especially respiratory diseases. Influenza and COVID-19 have emerged as two of the most significant respiratory pandemics, each with unique epidemic characteristics and far-reaching consequences. Our comparative analysis reveals that while both diseases exhibit high transmission rates, COVID-19's longer incubation period and higher severity have led to more profound and prolonged socioeconomic disruptions than influenza. Both pandemics have highlighted the exacerbating effects of climate change, with extreme weather events intensifying the spread and impact of these diseases. The COVID-19 pandemic exposed vulnerabilities in global healthcare systems and economies on an unprecedented scale, outstripping the strain caused by influenza outbreaks. Importantly, the COVID-19 pandemic has not only reshaped global public health strategies but also significantly impacted the epidemiology of influenza. Despite these differences and associations, both diseases underscore the urgent need for robust pandemic preparedness and adaptable public health strategies. This review delineates the overlaps and distinctions between influenza and COVID-19, offering insights into future challenges and the critical steps needed to enhance healthcare system resilience and improve global responses to pandemics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895011 | PMC |
http://dx.doi.org/10.1016/j.bsheal.2024.10.001 | DOI Listing |
Nanomedicine (Lond)
March 2025
Department of Chemistry and The Institute for Laser, Photonics, and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Background: Nanomedicine offers a number of innovative strategies to address major public health burdens, including complex respiratory illnesses. In this work, we introduce a multi-drug nanoparticle fabricated using femtosecond laser ablation for the treatment of influenza, SARS-CoV-2, and their co-infections.
Methods: The SARS-CoV-2 antiviral, remdesivir; the influenza antiviral, baloxavir marboxil; and the anti-inflammatory, dexamethasone, were co-crystalized and then ablated in aqueous media using a femtosecond pulsed laser and subsequently surface modified with the cationic polymer, chitosan, or poly-d-lysine.
Biosaf Health
December 2024
Vanke School of Public Health, Tsinghua University, Beijing 100084, China.
In the last century, global pandemics have been primarily driven by respiratory infections, which consistently rank among the top 20 causes of death worldwide. The coronavirus disease 2019 (COVID-19) pandemic has underscored the intricate nature of managing multiple health crises simultaneously. In recent years, climate change has emerged as a major biosafety and population health challenge.
View Article and Find Full Text PDFFront Med (Lausanne)
February 2025
State Key Laboratory of Traditional Chinese Medicine Syndrome/The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Traditional Chinese medicine has been used for Coronavirus disease 2019 (COVID-19) as a therapeutic option. Lianhuaqingwen capsules (LHQW) are well-recognized for their efficacy, while Kegan Liyan oral liquid (KGLY), widely used for influenza treatment, has emerged as a promising candidate for COVID-19 therapy. This trial aims to assess whether KGLY is non-inferior to LHQW in treating mild COVID-19.
View Article and Find Full Text PDFExpert Rev Respir Med
March 2025
Chairman Medical Research and Training Committee, Healthway QualiMed Hospital, San Jose Del Monte, Bulacan, Philippines.
Introduction: All over the world, viral pneumonia has a significant impact on morbidity and mortality, especially among vulnerable populations. The most common respiratory viruses causing pneumonia include influenza virus, respiratory syncytial virus, adenoviruses and rhinovirus. The COVID-19 pandemic has changed the landscape of viral pneumonia and has reshaped our understanding of the role of viruses in this disease.
View Article and Find Full Text PDFVirol J
March 2025
MyGenome, ALPS Global Holding Berhad, Kuala Lumpur, Malaysia.
Messenger RNA (mRNA) vaccines have emerged as a transformative platform in modern vaccinology. mRNA vaccine is a powerful alternative to traditional vaccines due to their high potency, safety, and efficacy, coupled with the ability for rapid clinical development, scalability and cost-effectiveness in manufacturing. Initially conceptualized in the 1970s, the first study about the effectiveness of a mRNA vaccine against influenza was conducted in 1993.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!